-+ 0.00%
-+ 0.00%
-+ 0.00%

Curanex Pharmaceuticals Faces Securities Class Actions Over Alleged IPO Disclosure Failures

PUBT·10/19/2026 21:18:10
Curanex Pharmaceuticals Faces Securities Class Actions Over Alleged IPO Disclosure Failures
  • Curanex Pharmaceuticals faces two proposed securities class actions in New York state court over its August 2025 IPO disclosures.
  • Daymond Morales filed the first lawsuit on July 23, 2026; Robert Lovett filed the second on September 14, 2026.
  • Both complaints allege misleading disclosures about stock-price manipulation risks and deficiencies in underwriter due diligence and compliance controls.
  • The second lawsuit also targets former management and directors; both actions seek unspecified damages, rescission and other relief.
  • Neither complaint alleges fraud against the company, which intends to defend both preliminary-stage cases vigorously.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-047614), on October 19, 2026, and is solely responsible for the information contained therein.